Kezar Life Sciences Inc KZR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
0.85UNCH (UNCH)
Volume
14,504
Close
0.8547quote price arrow up+0.0162 (+1.932%)
Volume
641,819
52 week range
0.67 - 3.13
Loading...
  • Open0.84
  • Day High0.8679
  • Day Low0.8339
  • Prev Close0.8385
  • 52 Week High3.13
  • 52 Week High Date06/07/23
  • 52 Week Low0.67
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap62.223M
  • Shares Out72.80M
  • 10 Day Average Volume0.59M
  • Dividend-
  • Dividend Yield-
  • Beta0.26
  • YTD % Change-9.78

KEY STATS

  • Open0.84
  • Day High0.8679
  • Day Low0.8339
  • Prev Close0.8385
  • 52 Week High3.13
  • 52 Week High Date06/07/23
  • 52 Week Low0.67
  • 52 Week Low Date11/13/23
  • Market Cap62.223M
  • Shares Out72.80M
  • 10 Day Average Volume0.59M
  • Dividend-
  • Dividend Yield-
  • Beta0.26
  • YTD % Change-9.78

RATIOS/PROFITABILITY

  • EPS (TTM)-1.40
  • P/E (TTM)-0.61
  • Fwd P/E (NTM)-0.63
  • EBITDA (TTM)-104.171M
  • ROE (TTM)-44.54%
  • Revenue (TTM)7.00M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,455.29%
  • Debt To Equity (MRQ)5.37%

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Kezar Life Sciences Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus...
Graham Cooper
Independent Chairman of the Board
Christopher Kirk Ph.D.
Chief Executive Officer, Director
Marc Belsky
Chief Financial Officer, Secretary
Address
4000 Shoreline Ct Ste 300
South San Francisco, CA
94080-2005
United States

Top Peers

SYMBOLLASTCHG%CHG
KRON
Kronos Bio Inc
1.03UNCHUNCH
IKNA
Ikena Oncology Inc
1.32+0.02+1.54%
LVTX
LAVA Therapeutics NV
3.10+0.13+4.38%
CUE
Cue Biopharma Inc
1.88-0.03-1.31%
MNOV
MediciNova Inc
1.35+0.06+4.65%